prodchem
Aug 20, 2026
Khartis Therapeutics' $50 million Series B brings together six named investors across its Series A and B financing history, creating a relatively broad syndicate for an emerging biotech company. The Series B was led by Forge Life Science Partners, with Longwood Fund and Alexandria Venture Investments joining existing investors Foresite Capital, Lilly Asia Ventures and Nextech Invest. The financing brings Khartis's total funding to $95 million.
For biotech investors, founders and industry observers, the composition is notable because it combines specialist healthcare investors with strategic and geographically diverse capital sources.
Khartis's investor group consists of:
Forge Life Science Partners
Longwood Fund
Alexandria Venture Investments
Foresite Capital
Lilly Asia Ventures
Nextech Invest
Three investors participated in the new Series B alongside three existing backers.
That structure gives Khartis a combination of new capital and continuing investor support rather than relying entirely on a new group of financiers.
A funding round is not defined only by the amount raised.
The investor group can influence:
Future fundraising
Clinical development strategy
Industry relationships
Business development
Hiring
Commercial planning
Access to follow-on capital
For an early-stage biotech moving toward clinical development, these factors can be particularly important.
Series B funding typically supports a company as it moves beyond early discovery toward more advanced development.
Khartis plans to use the new financing to advance its lead program, an oral selective IGF-1R inhibitor for thyroid eye disease (TED), while continuing development of its broader oral small-molecule immunology pipeline.
This makes the investor syndicate especially relevant as the company approaches more capital-intensive development milestones.
Foresite Capital, Lilly Asia Ventures and Nextech Invest were existing investors that participated in the Series B.
Continued participation can provide an important signal of investor confidence.
It can also reduce the need for a company to rebuild its investor base completely at every financing stage.
Forge Life Science Partners led the Series B, while Longwood Fund and Alexandria Venture Investments joined the financing.
Bringing new investors into a later financing round can expand a biotech's network while increasing access to additional expertise and capital.
This creates a structure combining:
Existing conviction + New capital + Broader investor network
Some biotech financings are dominated by one lead investor and a small number of participants.
Khartis's six named investors create a broader capital network.
This can provide advantages if the company requires additional financing later, although a larger investor group can also mean more stakeholders with different expectations.
Biotech funding differs from general technology financing because investors often need to understand:
Drug development
Clinical risk
Regulatory pathways
Intellectual property
Therapeutic markets
Manufacturing
Commercialization
Khartis's investor group includes firms with healthcare and life-sciences investment experience, making sector expertise an important component of the syndicate.
With the Series B, Khartis has raised $95 million in total.
For an emerging biotech, accumulated capital can provide greater flexibility to advance programs before returning to the market for another financing.
That can be particularly valuable when development timelines are uncertain.
Khartis is developing an oral selective IGF-1R inhibitor specifically for thyroid eye disease.
The company positions the program as an oral alternative within a disease area where existing treatment approaches can involve injectable therapies.
The financing therefore combines a relatively broad investor base with a clearly defined lead clinical opportunity.
A diverse investor group can potentially make future financing easier by providing multiple sources of follow-on capital.
If Khartis reaches important development milestones, existing investors may have incentives to maintain their positions while new investors could enter at later stages.
This can create a financing pathway such as:
Series A → Series B → Clinical milestones → Series C or strategic financing
The Khartis financing provides a useful example of how emerging biotech companies can build investor networks around specialized drug-development programs.
Investors evaluating similar companies should consider:
How concentrated is the funding base?
Do participants have relevant biotech expertise?
Are earlier investors continuing to participate?
Can the lead investor support future rounds?
Is the financing sufficient for the next major milestone?
For biotech founders, Khartis demonstrates the potential value of building an investor syndicate progressively.
New investors can bring fresh capital and networks, while existing investors provide continuity.
The objective is not simply to maximize the number of investors.
It is to create a group capable of supporting the company through increasingly expensive development stages.
Khartis's six-investor syndicate stands out because it combines three existing investors with three new participants around a $50 million Series B.
The structure gives the company access to a broader network as it advances its oral immunology pipeline toward clinical development.
For biotech investors, the financing is a useful benchmark for evaluating syndicate composition, investor continuity and capital concentration.
For pharmaceutical and life-science companies, it also highlights how specialized investor networks can help fund emerging therapeutic platforms.
The broader lesson is that the composition of a biotech funding round can be nearly as informative as the headline dollar amount. A well-balanced syndicate can provide not only capital, but also expertise, relationships and potential support for the next stage of development.
Khartis raised $50 million in Series B financing, bringing total funding to $95 million.
The Series B was led by Forge Life Science Partners.
Longwood Fund and Alexandria Venture Investments joined existing investors Foresite Capital, Lilly Asia Ventures and Nextech Invest.
The six named investors create a relatively broad syndicate for an emerging biotech.
Existing-investor participation provides continuity while new investors expand the company's capital network.
The financing will support Khartis's oral IGF-1R program for thyroid eye disease and its broader immunology pipeline.
A diversified investor base can provide additional options for future fundraising.
Investor expertise can be particularly valuable as biotech programs move toward clinical development.
Syndicate composition should be evaluated alongside funding size, development stage and investor commitment.
Khartis offers a useful 2026 benchmark for understanding how emerging biotech companies structure later-stage private financing.
Featured Product
Found this useful?
Continue Reading
BASF rebuilt from almost nothing after the 1952 IG Farben breakup to become the world's largest chemical company. Now its home site in Ludwigshafen is shrinking again, though not without limits. Here is how the two moments compare.
The Rhine's historically low water levels are creating a growing logistics problem for Europe's chemical industry. C&EN's August 18 Business Watch identifies Covestro as the latest affected producer, following BASF's earlier force majeure, making the expanding company tally an important benchmark for assessing the summer's cumulative disruption.
Khartis's $95 million total raise and InduPro's $77 million Series B highlight sustained investor interest in immunology and chronic disease biotechnology. Their funding levels also show how substantial capital is supporting emerging companies as they advance novel therapies through clinical development and regulatory milestones.
